
iSeed exits MySugr in trade sale to Roche
Swiss pharmaceutical business Roche Holding has purchased Austrian diabetes application developer MySugr, enabling the exit of VC backers.
MySugr will continue to operate as an independent brand in the group and plans to expand its teams in Vienna and San Diego. The acquisition is part of Roche's new diabetes care strategy.
In March 2015, iSeed Ventures led a $4.8m funding round for MySugr. Roche Ventures and XLHealth also participated in the round. It was iSeed's first investment outside of the US and China.
Company
Founded in 2012 and headquartered in Vienna, MySugr provides digital services for people with diabetes. The business develops the MySugr Logbook app for diabetes management, which operates on a freemium ad-supported model, and runs the MySugr Academy education platform. The company employs around 70 people.
People
MySugr – Frank Westermann (CEO).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater